SEC Info - Accelerate Diagnostics, Inc.

SEC Info℠

Home

Help

Please Sign In

Accelerate Diagnostics, Inc. – ‘8-K’ for 9/29/22

On: Monday, 10/3/22, at 5:26pm ET · For: 9/29/22 · Accession #: 1104659-22-105381 · File #: 1-31822

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/03/22  Accelerate Diagnostics, Inc.      8-K:8       9/29/22   10:186K                                   Toppan Merrill/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 5: R1          Cover                                               HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- tm2227310d1_8k_htm                  XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- axdx-20220929_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- axdx-20220929_pre              XML     64K 
 2: EX-101.SCH  XBRL Schema -- axdx-20220929                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
10: ZIP         XBRL Zipped Folder -- 0001104659-22-105381-xbrl      Zip     15K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0000727207 i false 0000727207 2022-09-29 2022-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported) i September 29, 2022

i Accelerate Diagnostics, Inc.

(Exact name of registrant as specified in charter)

i Delaware

(State or other jurisdiction of incorporation)

i 001-31822		i 84-1072256
(Commission File Number)		(IRS Employer Identification No.)

i 3950 South Country Club Road, i Suite 470, i Tucson, i Arizona		i 85714
(Address of principal executive offices)		(Zip Code)

( i 520) i 365-3100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which
registered

i Common Stock, $0.001 par value per share

i AXDX

i The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01.

Other Events.

As previously announced, on March 24, 2022, Accelerate Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”) for the issuance and sale by the Company of an aggregate of an aggregate of 2,439,024 shares of the Company’s common stock (the “Shares”) to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022. All other terms of the Securities Purchase Agreement remain unchanged.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACCELERATE DIAGNOSTICS, INC.
	(Registrant)
Date: October 3, 2022
	/s/ *Steve Reichling*
	Steve Reichling
	Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

	12/30/22
Filed on:	10/3/22
For Period end:	9/29/22
	9/26/22
	6/30/22	10-Q, 8-K
	6/29/22	8-K
	3/24/22	8-K
		List all Filings

↑Top

Filing Submission 0001104659-22-105381 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)